AlphaCentric Advisors LLC Raises Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

AlphaCentric Advisors LLC lifted its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 55.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 201,500 shares of the biopharmaceutical company's stock after acquiring an additional 71,500 shares during the quarter. Dynavax Technologies accounts for about 1.7% of AlphaCentric Advisors LLC's holdings, making the stock its 13th largest position. AlphaCentric Advisors LLC owned about 0.15% of Dynavax Technologies worth $2,245,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of DVAX. GAMMA Investing LLC boosted its position in Dynavax Technologies by 175.5% during the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 1,685 shares during the period. US Bancorp DE boosted its holdings in Dynavax Technologies by 291.4% in the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 2,034 shares during the period. Nisa Investment Advisors LLC grew its stake in Dynavax Technologies by 44.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company's stock valued at $61,000 after buying an additional 1,679 shares in the last quarter. Algert Global LLC bought a new stake in Dynavax Technologies during the 2nd quarter valued at $140,000. Finally, Sanctuary Advisors LLC purchased a new stake in shares of Dynavax Technologies during the second quarter worth $182,000. Hedge funds and other institutional investors own 96.96% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. HC Wainwright reiterated a "buy" rating and set a $29.00 price objective on shares of Dynavax Technologies in a research note on Tuesday, October 15th. The Goldman Sachs Group cut their price objective on shares of Dynavax Technologies from $20.00 to $15.00 and set a "neutral" rating for the company in a research report on Thursday, August 8th.

Dynavax Technologies Price Performance

Shares of NASDAQ:DVAX traded up $0.23 on Tuesday, hitting $12.02. The company's stock had a trading volume of 1,513,052 shares, compared to its average volume of 2,092,152. The company has a market capitalization of $1.58 billion, a PE ratio of 107.19 and a beta of 1.34. The company has a debt-to-equity ratio of 0.35, a current ratio of 14.18 and a quick ratio of 13.18. The company has a 50-day simple moving average of $11.07 and a 200 day simple moving average of $11.22. Dynavax Technologies Co. has a 1 year low of $9.74 and a 1 year high of $15.01.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.02. Dynavax Technologies had a net margin of 6.88% and a return on equity of 2.76%. The company had revenue of $73.80 million during the quarter, compared to analyst estimates of $76.92 million. During the same period in the previous year, the business earned $0.03 earnings per share. Sell-side analysts forecast that Dynavax Technologies Co. will post 0.16 EPS for the current fiscal year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.